MDRNA Begins Primate Studies in Liver Cancer Program, Adds Bladder Cancer to Pipeline

MDRNA also reported its second-quarter financial results last week, posting a nearly 50 percent drop in its net loss despite decreased revenues. The company attributed the improvement to decreased costs following its completed transition from the clinical-stage intranasal drug-delivery shop Nastech Pharmaceuticals to a preclinical RNAi-therapeutics developer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.